MedPath

Tagged News

Absci Raises $50 Million to Advance AI-Driven Drug Discovery Platform and Internal Pipeline

AIDrug Discovery
  • Absci Corporation completed a $50 million public offering of 16.67 million shares at $3.00 per share to fund its AI-powered drug discovery programs and internal pipeline development.
  • The company's cash reserves increased to $134 million as of March 2025, extending its operational runway through 2027 while advancing preclinical candidates ABS-101 and ABS-201.
  • Absci's Integrated Drug Creation platform combines generative AI with synthetic biology and has secured partnerships with pharmaceutical giants including Merck and Moderna.
  • The AI-driven biologics market is projected to grow from $13.9 billion in 2024 to over $30 billion by 2030, positioning Absci in a rapidly expanding sector.

CDx Diagnostics Receives FDA Breakthrough Device Designation for AI-Powered WATS3D Esophageal Cancer Diagnostic System

AI
  • CDx Diagnostics received FDA Breakthrough Device Designation for its WATS3D diagnostic system, a first-of-a-kind AI-powered digital pathology platform for diagnosing Barrett's esophagus and early neoplastic changes.
  • The system demonstrated superior effectiveness compared to the Seattle biopsy protocol in large multi-center studies involving over 23,000 patients for detecting dysplasia and esophageal cancer.
  • The WATS3D Test leverages artificial intelligence and 3D digital imaging to identify precancerous and cancerous cells, potentially detecting early-stage disease missed by conventional biopsies.
  • The diagnostic platform has analyzed over 400,000 patient samples and aims to improve early detection of patients at risk for esophageal cancer progression.

Turbine Partners with AstraZeneca to Accelerate ADC Discovery Using AI-Powered Virtual Disease Models

AIDrug DiscoveryOncology
  • Turbine announced a collaboration with AstraZeneca to apply AI-powered virtual disease models for rationalizing antibody-drug conjugate (ADC) discovery and reducing large-scale cell line screening requirements.
  • The partnership implements a lab-in-the-loop approach where Turbine's platform recommends strategic cell line subsets for testing and predicts outcomes across thousands of in silico models using AstraZeneca's ADC datasets.
  • The collaboration aims to move beyond broad experimental screening toward targeted strategies that enhance clinical translatability by providing mechanistic insights into treatment response and resistance mechanisms.
  • This builds on previous successful collaborations between the companies in hematological cancer research and DNA damage repair mechanisms, supporting Turbine's mission to accelerate drug discovery through virtual experimentation.

Harvard AI Model PDGrapher Accelerates Drug Discovery by Predicting Cellular Disease Reversal

AIDrug Discovery
  • Harvard Medical School researchers developed PDGrapher, an AI model that identifies cellular changes to reverse disease states, offering a new approach to drug discovery beyond traditional single-target methods.
  • The graph neural network-based tool demonstrated superior performance in testing, ranking correct targets up to 35% higher than similar models while delivering results up to 25 times faster across 19 datasets from 11 cancer types.
  • PDGrapher successfully identified known drug targets including KDR (VEGFR2) for non-small cell lung cancer and TOP2A for tumor spread, confirming its clinical relevance and potential for personalized treatment design.

Flatiron Health Triples Global Oncology Research Network, Expanding Real-World Data Access Across Three Countries

AIPrecision Medicine
  • Flatiron Health's international oncology research network has tripled in size over the past year, now encompassing more than 30 partnerships across the UK, Germany, and Japan.
  • The expansion brings Flatiron's total patient database above 5 million records, with new partnerships including major academic medical centers and national cancer centers in each country.
  • The company established Flatiron FORUM, a global consortium addressing data transportability challenges to support multinational cancer research and regulatory decisions.
  • Seven research studies using multinational real-world data have been completed within the past two years, demonstrating the platform's capability for cross-country cohort analyses.

AI-Guided Drug LP-284 Achieves Complete Response in Treatment-Resistant Lymphoma Patient

AIOrphan Drug
  • Lantern Pharma's LP-284 achieved complete metabolic response in a heavily pretreated diffuse large B-cell lymphoma patient after just two treatment cycles.
  • The 41-year-old patient had previously failed three aggressive treatment regimens including CAR-T therapy and bispecific antibody therapy over 18 months.
  • LP-284 was developed using Lantern's RADR® AI platform in under three years at approximately $3 million, demonstrating computational efficiency in drug development.
  • The synthetic lethal therapy targets cancer cells with DNA damage repair deficiencies while preserving healthy tissue function.

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients with Relapsed or Refractory Lymphomas and Solid Tumors

NCT06132503RecruitingPhase 1
Lantern Pharma Inc.
Posted 1/3/2023

IGC Pharma Unveils AI-Powered Alzheimer's Platforms at AAIC 2025

AIDrug Discovery
  • IGC Pharma will present three scientific posters at the 2025 Alzheimer's Association International Conference showcasing proprietary AI platforms for drug discovery and early disease detection.
  • The company's MINT-AD platform uses large language models to predict cognitive decline scores using only socioeconomic data, eliminating the need for brain scans or blood biomarkers.
  • IGC's hybrid AI-powered screening pipeline rapidly identifies interactions between proprietary molecules and Alzheimer's targets including GLP-1 and CB1 receptors.
  • The innovations aim to expand access to earlier diagnosis and accelerate therapeutic discovery, particularly in low-resource settings.

Apollo Hospitals and Siemens Healthineers Launch AI-Driven Research Collaboration for Liver Disease Diagnostics in India

AI
  • Apollo Hospitals and Siemens Healthineers have established a research collaboration to develop AI-enabled diagnostic and imaging solutions for liver disease management, focusing on quantitative ultrasound imaging and clinical decision support tools.
  • The partnership specifically targets Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects 9-32% of India's population and poses significant diagnostic challenges due to its underestimated prevalence.
  • The collaboration aims to enhance early detection of liver fibrosis through AI-driven disease progression models, enabling timely interventions and cost-effective screening for improved patient outcomes.
  • A Master Research Agreement was formalized in March 2025, with an addendum signed in July 2025 establishing the framework for collaborative research on diagnostic and interventional ultrasound imaging for liver care.

SurgiVance Secures $2.2M NIH Grant to Advance Direct-to-Digital Pathology Platform

AIPrecision Medicine
  • SurgiVance Inc. received a $2,245,000 National Cancer Institute Small Business Innovation Research Direct-to-Phase II grant to commercialize its "pathology lab-in-a-box" technology.
  • The platform enables direct-to-digital, in-office pathology using advanced imaging hardware and AI processing on whole tissue without traditional glass microscope slides.
  • Clinical studies will be conducted at NYU Langone Health, The Rockefeller University, Northwell Health, and Oregon Health & Science University targeting cancer at cellular and molecular levels.
  • The technology promises to deliver histopathologic diagnosis in minutes, potentially transforming cancer management and precision medicine through 3D molecular imaging biomarkers.

Answer ALS Launches AI-Powered Drug Discovery Initiative to Accelerate ALS Treatment Development

AIDrug Discovery
  • Answer ALS has launched LADDIA, a groundbreaking AI-powered drug discovery collaboration with GATC Health, Pennington Biomedical Research Center, and Tulane University to accelerate ALS treatment development.
  • The initiative leverages the world's largest open-access ALS dataset through the Neuromine Data Portal and GATC Health's proprietary AI platform to identify druggable therapeutic targets.
  • Currently, there are no known viable treatments for ALS, making this AI-driven approach critical for identifying new therapeutic pathways for the neurodegenerative disease.
  • The collaboration will roll out in two phases, focusing first on building infrastructure and then activating collaborative projects to generate high-impact scientific outputs.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.